Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 2Phase 1 1

Status

Completed 57Terminated 23Recruiting 7Withdrawn 6Active not recruiting 5Unknown 4Not yet recruiting 2Suspended 1

Sponsor Class

OTHER 4INDUSTRY 1

Study Type

Interventional 5

Sponsor

Cancer Type

Dermatologic 5Thoracic 3Head & Neck 3Genitourinary 1Gastrointestinal 1

Conditions

Melanoma 5Carcinoma, Renal Cell 4Squamous Cell Carcinoma of Head and Neck 3Neoplasms 2Lung Neoplasms 2Urogenital Neoplasms 1Solid Tumor, Adult 1Recurrence 1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Mesothelioma, Malignant 1Meningeal Neoplasms 1Lymphoma, B-Cell 1Lymphoma 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1Kidney Neoplasms 1Head and Neck Neoplasms 1Fallopian Tube Neoplasms 1Disease Progression 1Colorectal Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Squamous Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 62Nivolumab 40Ipilimumab 24trametinib 13dabrafenib 10Specimen Handling 10Magnetic Resonance Spectroscopy 10binimetinib 9Cyclophosphamide 8CTLA-4 Antigen 8Biopsy 8encorafenib 7fludarabine 6Radiosurgery 6Cisplatin 6relatlimab 5cemiplimab 5atezolizumab 5Pemetrexed 5Introns 5Interleukin-2 5tislelizumab 4lenvatinib 4fludarabine phosphate 4durvalumab 4dostarlimab 4cobimetinib 4avelumab 4Radiotherapy 4Paclitaxel 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Active not recruiting × Melanoma × Interleukin-2 × Clear all
NCT01416831 2026-04-24

SBRT/IL-2

Providence Health & Services

Phase 2 Active not recruiting
44 enrolled 12 charts
Dermatologic

Melanoma

NCT00338377 2026-03-20

Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization in Patients With Metastatic Melanoma

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
1,230 enrolled
Dermatologic

Melanoma, Meningeal Neoplasms

NCT06237881 2026-02-18

A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid Tumors

M.D. Anderson Cancer Center

Phase 1/2 Active not recruiting
15 enrolled
DermatologicHead & NeckThoracic

Head and Neck Neoplasms, Lung Neoplasms, Melanoma

NCT03474497 2026-01-29

UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade

University of California, Davis

Phase 1/2 Active not recruiting
18 enrolled 13 charts
DermatologicGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma

NCT05902520 2026-01-08

ACT

AgonOx, Inc.

Phase 1 Active not recruiting
18 enrolled
DermatologicGastrointestinalHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Lung Neoplasms, Melanoma, Neoplasms, Urogenital Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡